63: Vaccination with dendritic cell myeloma fusions alone or in conjunction with stem cell transplantation for patients with multiple myeloma

David Avigan(Beth Israel Deaconess Medical Center), Donald Küfe(Dana-Farber Cancer Institute), C. Lenahan(Beth Israel Deaconess Medical Center), Lynne Uhl(Hadassah Medical Center), Nikhil C. Munshi(Dana-Farber Cancer Institute), D. Donbagoda(Hadassah Medical Center), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), K B Miller(Tufts Medical Center), P. Forino(Beth Israel Deaconess Medical Center), JoAnn Proper(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), C. Macnamarra(Beth Israel Deaconess Medical Center), Zhiyou Wu(Dana-Farber Cancer Institute), A. Bisonette(Harvard University), J Levine, Robin Joyce(Beth Israel Deaconess Medical Center)
Transplantation and Cellular Therapy
January 26, 2007
10.1016/j.bbmt.2006.12.066
Cited by 0

Related Papers

Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k